Arch Dis Child 2001;84:227-229 ( March )

Article

Short report

Idiopathic thrombocytopenic purpura and MMR vaccine E Miller^a, P Waight^a, C P Farrington^b, N Andrews^a, J Stowe^c, B Taylor^c

^a Immunisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, Colindale, London NW9 5EQ, UK, ^b Department of Statistics, The Open University, Milton Keynes MK7 6AA, UK, ^c Royal Free Campus, Royal Free and University College Medical School, University College London, London NW3 2PF, UK

Correspondence to: Dr Miller e.miller{at}phls.co.uk

Accepted 11 April 2000

A CAUSAL ASSOCIATION BETWEEN MEASLESmumps-rubella (MMR) vaccine and idiopathic thrombocytopenic purpura (ITP) was confirmed using immunisation/hospital admission record linkage. The absolute risk within six weeks of immunisation was 1 in 22 300 doses, with two of every three cases occurring in the six week post-immunisation period being caused by MMR. Children with ITP before MMR had no vaccine associated recurrences.


Keywords: MMR; vaccine; idiopathic thrombocytopenia purpura

---

© 2001 by Archives of Disease in Childhood
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Whitaker, H. J, Hocine, M. N, Farrington, C P. (2009). The methodology of self-controlled case series studies. Stat Methods Med Res 18: 7-26 [Abstract]  
• Bibby, A. C, Farrell, A., Cummins, M., Erlewyn-Lajeunesse, M. (2008). Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?. Arch. Dis. Child. 93: 354-355 [Full Text]  
• Braun, M. M. (2008). Toward Better Vaccine Safety Data and Safer Vaccination. Pediatrics 121: 625-626 [Full Text]  
• Glanz, J., France, E., Xu, S., Hayes, T., Hambidge, S. (2008). A Population-Based, Multisite Cohort Study of the Predictors of Chronic Idiopathic Thrombocytopenic Purpura in Children. Pediatrics 121: e506-e512 [Abstract] [Full Text]  
• France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., Belongia, E. A., Hohman, K., Chen, R. T., Davis, R., for the Vaccine Safety Datalink Team, (2008). Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children. Pediatrics 121: e687-e692 [Abstract] [Full Text]  
• Stowe, J., Kafatos, G., Andrews, N., Miller, E. (2008). Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch. Dis. Child. 93: 182-183 [Full Text]  
• Taylor, B., Andrews, N., Stowe, J., Hamidi-Manesh, L., Miller, E. (2007). No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Arch. Dis. Child. 92: 887-889 [Abstract] [Full Text]  
• Wise, R. P., Iskander, J., Pratt, R. D., Campbell, S., Ball, R., Pless, R. P., Braun, M. M. (2004). Postlicensure Safety Surveillance for 7-Valent Pneumococcal Conjugate Vaccine. JAMA 292: 1702-1710 [Abstract] [Full Text]  
• Fitzpatrick, M. (2004). MMR: risk, choice, chance. Br Med Bull 69: 143-153 [Abstract] [Full Text]  
• Boehlen, F, Balavoine, J-F, de Moerloose, P (2003). Severe thrombocytopenic purpura due to rubella infection in a patient with systemic lupus erythematosus. Lupus 12: 144-146 [Abstract]  
• Ki, M., Park, T., Yi, S. G., Oh, J. K., Choi, B. (2003). Risk Analysis of Aseptic Meningitis after Measles-Mumps-Rubella Vaccination in Korean Children by Using a Case-Crossover Design. Am J Epidemiol 157: 158-165 [Abstract] [Full Text]  
• Salisbury, D M, Beverley, P C L, Miller, E (2002). Vaccine programmes and policies. Br Med Bull 62: 201-211 [Abstract] [Full Text]  
• Danovaro-Holliday, M. C., Wood, A. L., LeBaron, C. W. (2002). Rotavirus Vaccine and the News Media, 1987-2001. JAMA 287: 1455-1462 [Abstract] [Full Text]  
• Abramson, J. S., Pickering, L. K. (2002). US Immunization Policy. JAMA 287: 505-509 [Full Text]  
• (2001). Other Articles Noted. Evid. Based Nurs. 4: E1-11 [Full Text]